Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544149 | 0.78 | MAPT (0.55) | PTGDR2APPMAPTNPC1KDM4E | |
| SCHEMBL8187274 | 0.78 | MAPT (0.60) | PTGDR2APPMAPTNPC1KDM4E | |
| SCHEMBL1920654 | 0.76 | FFAR1 (0.57) | PTGDR2APPMAPTNPC1KDM4E | |
| SCHEMBL31279173 | 0.76 | FFAR1 (0.57) | PTGDR2APPMAPTNPC1KDM4E | |
| SCHEMBL29429035 | 0.74 | MAPT (0.60) | APPMAPTNPC1KDM4EMEN1 | |
| SCHEMBL29001487 | 0.74 | APP (0.44) | APPMAPTNPC1KDM4EMEN1 | |
| SCHEMBL16478272 | 0.74 | APP (0.40) | PTGDR2APPMAPTNPC1KDM4E | |
| SCHEMBL15895659 | 0.74 | FFAR1 (0.44) | PTGDR2APPMAPTNPC1KDM4E | |
| SCHEMBL1921687 | 0.74 | ACACB (0.53) | APPNPC1MEN1CYP1A2KMT2A | |
| SCHEMBL20886674 | 0.73 | APP (0.48) | APPMAPTNPC1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | disclosed |
| EP-2134682-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF N-AMINOINDOLES | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-8026375-B2 | Transition metal catalyzed synthesis of N-aminoindoles | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| EP-2170833-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI AVENTIS (FR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
| US-20100168429-A1 | Transition metal catalyzed synthesis of N-aminoindoles | SANOFI-AVENTIS (FR) | 2010-07-01 | — | — | US | disclosed |
| EP-2170833-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| EP-2134682-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF N-AMINOINDOLES | Sanofi-Aventis (FR) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009000411-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008125207-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF N-AMINOINDOLES | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168429-A1 | Transition metal catalyzed synthesis of N-aminoindoles | NAT1, H1-3, H1-2 | PTGDR2 1904/4885APP 3821/4885MAPT 2698/4885 |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | H1-3, H1-2, H1-4 | PTGDR2 1691/4885APP 4673/4885MAPT 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.